TY - JOUR
T1 - Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma
AU - Maruyama, Dai
AU - Watanabe, Takashi
AU - Heike, Yuji
AU - Nagase, Kumiko
AU - Takahashi, Noriko
AU - Yamasaki, Satoshi
AU - Waki, Fusako
AU - Yokoyama, Hiroki
AU - Kim, Sung Won
AU - Kobayashi, Yukio
AU - Aizawa, Shin
AU - Tobinai, Kensei
N1 - Funding Information:
Acknowledgments We thank Janssen Pharmaceutical K.K. for supporting the measurement of serum cytokines of the patients enrolled in this study. We also thank Ms. Junko Nomoto, a medical technologist of the Hematology Division at the National Cancer Center Hospital, for her helpful advice regarding PCR methods. This work was supported in part by a Grant-in-Aid for Cancer Research (17-17) from the Ministry of Health, Labor and Welfare, Tokyo, Japan (Takashi Watanabe).
PY - 2008/11
Y1 - 2008/11
N2 - Bortezomib blocks the activation of nuclear factor-κB-mediated pro-inflammatory cytokines, however, systemic inflammatory symptoms following bortezomib administration have been reported, although their mechanisms remain elusive. Serum samples were obtained from five patients, who participated in a phase I/II study of Japanese patients with relapsed or refractory multiple myeloma (MM), and developed cyclic fever following bortezomib administration, to measure cytokine levels. Significant correlations between interleukin (IL)-6 or interferon (IFN)-γ and the body temperature were observed in two patients each. Furthermore, we found that IL-6 elevation was not observed after the addition of bortezomib to any examined MM cells alone, but was noted in a case of bone marrow stromal cells (BMSCs) of macrophage origin alone or co-cultured with MM cells. Similarly, a marked increase in IFN-γ levels was induced by adding bortezomib to BMSCs of fibroblast origin. Although this investigation was a preliminary study with a small number of patients, our results suggested that pro-inflammatory cytokines causing bortezomib-associated fever were secreted from BMSCs rather than MM cells.
AB - Bortezomib blocks the activation of nuclear factor-κB-mediated pro-inflammatory cytokines, however, systemic inflammatory symptoms following bortezomib administration have been reported, although their mechanisms remain elusive. Serum samples were obtained from five patients, who participated in a phase I/II study of Japanese patients with relapsed or refractory multiple myeloma (MM), and developed cyclic fever following bortezomib administration, to measure cytokine levels. Significant correlations between interleukin (IL)-6 or interferon (IFN)-γ and the body temperature were observed in two patients each. Furthermore, we found that IL-6 elevation was not observed after the addition of bortezomib to any examined MM cells alone, but was noted in a case of bone marrow stromal cells (BMSCs) of macrophage origin alone or co-cultured with MM cells. Similarly, a marked increase in IFN-γ levels was induced by adding bortezomib to BMSCs of fibroblast origin. Although this investigation was a preliminary study with a small number of patients, our results suggested that pro-inflammatory cytokines causing bortezomib-associated fever were secreted from BMSCs rather than MM cells.
UR - http://www.scopus.com/inward/record.url?scp=64249112700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64249112700&partnerID=8YFLogxK
U2 - 10.1007/s12185-008-0194-0
DO - 10.1007/s12185-008-0194-0
M3 - Article
C2 - 18989635
AN - SCOPUS:64249112700
SN - 0925-5710
VL - 88
SP - 396
EP - 402
JO - International journal of hematology
JF - International journal of hematology
IS - 4
ER -